VOR BIOPHARMA INC
VORNASDAQTrading Snapshot
- Day Range
- $18.26 – $18.54
- 52-Week Range
- $6.50 – $49.95
- Volume
- $3.17B
- Avg Volume
- $2.22B
- Shares Outstanding
- 54.2M
- Next Earnings
- Nov 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $81M
- Last Q Revenue
- $18M
- P/E Ratio
- 1.8
- P/S Ratio
- —
- EPS (TTM)
- $-43.00
- Dividend Yield
- —
- Dilution (1yr)
- +187.4%
Why Investors Own VOR
- ✓High-growth profile — revenue up +41.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 40% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
VOR BIOPHARMA INC
VOR
StockOtter · stockotter.spaceAbout VOR BIOPHARMA INC
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over the
Vor Biopharma: A Funded Replication Story With Franchise Potential
Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a robust $514.5M liquidity position. VOR's global Phase 3 trials in myasthenia gravis and Sjögren's are fully enrolled or
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
Topline results from UPSTREAM MG's 24-week primary endpoint remain on track for first half of 2027 Global Phase 3 ocular myasthenia gravis (oMG) registrational trial, UPSTREAM oMG, broadens telitacicept development acros
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 1, 2026, the Compensation Com
Bank of America Corp DE Has $2.01 Million Stock Holdings in Vor Biopharma Inc. $VOR
Bank of America Corp DE increased its position in Vor Biopharma Inc. (NASDAQ: VOR) by 28,408.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 112,892 shares